Liu Lang, Zhang Yundi, Du Yuxin, Li Haoyue, Wang Mingzhao, Lv Jianfeng
Department of Cardiology, General Hospital of Ningxia Medical University, Yinchuan, China.
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Front Nutr. 2022 Oct 10;9:986639. doi: 10.3389/fnut.2022.986639. eCollection 2022.
Cellulose is the first rich biological polysaccharide in nature and has many excellent properties, so it is being developed as a variety of drug carriers. Moreover, applications in drug delivery, biosensors/bioanalysis, immobilization of enzymes and cells, stem cell therapy, and skin tissue repair are also highlighted by many studies. Coronary heart disease, as one of the diseases with the highest incidence, is urgent to enhance the survival outcome and life quality of patients with coronary heart disease, whereas the mechanism of cellulose's interaction with the human body remains unclear. However, the mechanism of cellulose's interaction with the human body remains unclear. We obtained 92 genes associated with cellulose and coronary heart disease through the intersection of different databases. Ten key genes were identified: HRAS, STAT3, HSP90AA1, FGF2, VEGFA, CXCR4, TERT, IL2, BCL2L1, and CDK1. Molecular docking of the 10 genes revealed their association with their respective receptors. Analysis by KEGG and GO has discovered that these related targets were more enriched in metabolic- and activation-related functions, which further confirmed that cellulose polysaccharides can also interact with cardiovascular diseases as molecules. In the end, we screened out six key genes that were more associated with the prognosis (CDK1, HSP90AA1, CXCR4, IL2, VEGFA, and TERT) and constructed a signature, which has a good predictive effect and has significant statistical significance. Our study is the first study to explore the interaction targets of cellulose and CHD and to construct a prognostic model. Our findings provide insights for future molecular design, drug development, and clinical trials.
纤维素是自然界中含量最丰富的生物多糖，具有许多优异的特性，因此正被开发为多种药物载体。此外，许多研究还强调了其在药物递送、生物传感器/生物分析、酶和细胞固定化、干细胞治疗以及皮肤组织修复等方面的应用。冠心病作为发病率最高的疾病之一，迫切需要提高冠心病患者的生存结局和生活质量，然而纤维素与人体相互作用的机制仍不清楚。我们通过不同数据库的交叉分析获得了92个与纤维素和冠心病相关的基因。确定了10个关键基因：HRAS、STAT3、HSP90AA1、FGF2、VEGFA、CXCR4、TERT、IL2、BCL2L1和CDK1。对这10个基因的分子对接揭示了它们与各自受体的关联。通过KEGG和GO分析发现，这些相关靶点在代谢和激活相关功能中富集程度更高，这进一步证实了纤维素多糖也可以作为分子与心血管疾病相互作用。最后，我们筛选出了六个与预后更相关的关键基因（CDK1、HSP90AA1、CXCR4、IL2、VEGFA和TERT）并构建了一个特征模型，该模型具有良好的预测效果且具有显著的统计学意义。我们的研究是首次探索纤维素与冠心病相互作用靶点并构建预后模型的研究。我们的发现为未来的分子设计、药物开发和临床试验提供了见解。
